The vascular and coagulation issues in xenotransplantation

Current Opinion in Organ Transplantation

Volumn 14, Issue 2, 2009, Pages 161-167

  Cowan, Peter J ^a,b   Roussel, Jean C ^c   D'Apice, Anthony J F ^a,b  

^a ST VINCENT S HOSPITAL   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c CHU de Nantes   (France)

Author keywords

Antibody; Coagulation; Complement; Endothelium; Xenograft

Indexed keywords

ALPHA 1,3 GALACTOSYLTRANSFERASE; CARBOHYDRATE; CD39 ANTIGEN; DESMOPRESSIN; ENDOTHELIAL PROTEIN C RECEPTOR; GAMMA INTERFERON; HIRUDIN; PROTEIN C; THROMBIN; THROMBOMODULIN; TIROFIBAN; TISSUE FACTOR PATHWAY INHIBITOR; ALPHA 1,3 GALACTOSYLTRANSFERASE 1, PORCINE; ALPHA GALACTOSYL EPITOPE; ALPHA-1,3-GALACTOSYLTRANSFERASE 1, PORCINE; ALPHA-GALACTOSYL EPITOPE; ANTIBODY; BLOOD CLOTTING INHIBITOR; COMPLEMENT; GALACTOSYLTRANSFERASE; TRISACCHARIDE;

ACUTE GRAFT REJECTION; BLOOD CLOTTING; BLOOD VESSEL INJURY; CELL ACTIVATION; CELL SURFACE; COMPLEMENT ACTIVATION; DNA MODIFICATION; ENDOTHELIUM CELL; EXPERIMENTAL PIG; GRAFT FAILURE; HEART TRANSPLANTATION; HUMAN; IMMUNOCOMPETENT CELL; INFLAMMATION; INNATE IMMUNITY; KIDNEY TRANSPLANTATION; KNOCKOUT GENE; NONHUMAN; REGULATORY MECHANISM; REVIEW; THROMBOCYTE; THROMBOTIC THROMBOCYTOPENIC PURPURA; XENOTRANSPLANTATION; ANIMAL; BLOOD; GENE INACTIVATION; GENETICS; GRAFT REJECTION; IMMUNOLOGY; METABOLISM; ORGAN TRANSPLANTATION; PRIMATE; SPECIES DIFFERENCE; SWINE; TRANSGENIC ANIMAL; TRANSPLANTATION TOLERANCE; VASCULAR DISEASE; VASCULAR ENDOTHELIUM; XENOGRAFT;

ANIMALS; ANIMALS, GENETICALLY MODIFIED; ANTIBODIES; BLOOD COAGULATION; BLOOD COAGULATION FACTOR INHIBITORS; COMPLEMENT SYSTEM PROTEINS; ENDOTHELIUM, VASCULAR; GALACTOSYLTRANSFERASES; GENE KNOCKOUT TECHNIQUES; GRAFT REJECTION; HUMANS; ORGAN TRANSPLANTATION; PRIMATES; SPECIES SPECIFICITY; SWINE; TRANSPLANTATION TOLERANCE; TRANSPLANTATION, HETEROLOGOUS; TRISACCHARIDES; VASCULAR DISEASES;

EID: 67651009394     PISSN: 10872418     EISSN: 15317013     Source Type: Journal    
DOI: 10.1097/MOT.0b013e3283279591     Document Type: Review

References (60)

1. Shimizu A, Hisashi Y, Kuwaki K, et al. Thrombotic microangiopathy associated with humoral rejection of cardiac xenografts from alpha1,3-galactosyltransferase gene-knockout pigs in baboons. Am J Pathol 2008; 172:1471-1481. This paper is important because it contains the first detailed report of the pathology of rejection of GalT KO solid organs in the pig-to-primate model. It provides valuable insights into the mechanisms behind the development of thrombotic microangiopathy, which is currently the major cause of failure of vascularized xenografts. (Pubitemid 351793341)
2. Yamada K, Yazawa K, Shimizu A, et al. Marked prolongation of porcine renal xenograft survival in baboons through the use of alpha1,3- galactosyltransferase gene-knockout donors and the cotransplantation of vascularized thymic tissue. Nat Med 2005; 11:32-34. (Pubitemid 40215834)
3. Chen G, Qian H, Starzl T, et al. Acute rejection is associated with antibodies to non-Gal antigens in baboons using Gal-knockout pig kidneys. Nat Med 2005; 11:1295-1298. (Pubitemid 41752909)
4. Cowan PJ, Salvaris EJ, Crikis S, et al. Gal KO pig renal xenografts are not hyperacutely rejected by nonimmunosuppressed baboons. Am J Transplant 2006; 6:1050.
5. Nottle MB, Beebe LF, Harrison SJ, et al. Production of homozygous alpha-1,3- galactosyltransferase knockout pigs by breeding and somatic cell nuclear transfer. Xenotransplantation 2007; 14:339-344. This study demonstrates for the first time that it is possible to produce pigs by cloning using GalT KO cells, which should permit faster incorporation of new genetic modifications onto the GalT KO background.
6. Fujimura T, Takahagi Y, Shigehisa T, et al. Production of alpha 1,3-galactosyltransferase gene-deficient pigs by somatic cell nuclear transfer: a novel selection method for gal alpha 1,3-Gal antigen-deficient cells. Mol Reprod Dev 2008; 75:1372-1378. (Pubitemid 352032525)
7. Kolber-Simonds D, Lai L, Watt SR, et al. Production of alpha-1,3-galactosyltransferase null pigs by means of nuclear transfer with fibroblasts bearing loss of heterozygosity mutations. Proc Natl Acad Sci U S A 2004; 101:7335-7340. (Pubitemid 38638033)
8. Hara H, Gridelli B, Lin YJ, et al. Liver xenografts for the treatment of acute liver failure: clinical and experimental experience and remaining immunologic barriers. Liver Transpl 2008; 14:425-434.
9. Ekser B, Rigotti P, Gridelli B, Cooper DKC. Xenotransplantation of solid organs in the pig-to-primate model. Transpl Immunol 2008. [Epub ahead of print]
10. Cowan PJ. Coagulation and the xenograft endothelium. Xenotransplantation 2007; 14:7-12.
11. Nankivell BJ, Chapman JR. Chronic allograft nephropathy: current concepts and future directions. Transplantation 2006; 81:643-654.
12. Christiansen D, Milland J, Mouhtouris E, et al. Humans lack iGb3 due to the absence of functional iGb3-synthase: implications for NKT cell development and transplantation. PLoS Biol 2008; 6:e172.
13. Kiernan K, Harnden I, Gunthart M, et al. The antinongal xenoantibody response to xenoantigens on gal knockout pig cells is encoded by a restricted number of germline progenitors. Am J Transplant 2008; 8:1829-1839. An interesting study suggesting that most antibodies directed against non-GalT carbohydrate xenoantigens bind to an epitope that is structurally related to, but distinct from, αGal.
14. Diswall M, Angstrom J, Schuurman HJ, et al. Studies on glycolipid antigens in small intestine and pancreas from alpha1,3-galactosyltransferase knockout miniature swine. Transplantation 2007; 84:1348-1356. (Pubitemid 351339324)
15. Saethre M, Baumann BC, Fung M, et al. Characterization of natural human antinongal antibodies and their effect on activation of porcine gal-deficient endothelial cells. Transplantation 2007; 84:244-250. The interest in this paper is in the large number of naïve human serum samples tested and the great variation that was observed in anti-non-GalT antibody titres and in the ability of individual sera to activate GalT KO endothelial cells. This situation may add to the unpredictability likely to be faced with clinical xenotransplantation and suggests the need for rigorous pretesting of human recipients. (Pubitemid 47205759)
16. Baumann BC, Stussi G, Huggel K, et al. Reactivity of human natural antibodies to endothelial cells from Galalpha(1,3)Gal-deficient pigs. Transplantation 2007; 83:193-201.
17. Ezzelarab M, Ayares D, Cooper DK. Carbohydrates in xenotransplantation. Immunol Cell Biol 2005; 83:396-404.
18. Morozumi K, Kobayashi T, Usami T, et al. Significance of histochemical expression of Hanganutziu-Deicher antigens in pig, baboon and human tissues. Transplant Proc 1999; 31:942-944. (Pubitemid 29127753)
19. Zhang M, Carroll MC. Natural antibody mediated innate autoimmune response. Mol Immunol 2007; 44:103-110. (Pubitemid 44647111)
20. Huber-Lang M, Sarma JV, Zetoune FS, et al. Generation of C5a in the absence of C3: a new complement activation pathway. Nat Med 2006; 12:682- 687. This paper is not from the field of xenotransplantation, but nevertheless may have a significant impact, because it demonstrates that human thrombin can directly activate C5 without the participation of earlier components of the complement pathway. In the procoagulant environment of the xenograft, this can potentially generate the membrane attack complex even in the presence of CD46 and CD55. (Pubitemid 43865238)
21. Selander B, Martensson U, Weintraub A, et al. Mannan-binding lectin activates C3 and the alternative complement pathway without involvement of C2. J Clin Invest 2006; 116:1425-1434.
22. McMullen ME, Hart ML, Walsh MC, et al. Mannose-binding lectin binds IgM to activate the lectin complement pathway in vitro and in vivo. Immunobiology 2006; 211:759-766.
23. Aird WC. Endothelium and allotransplantation. Transplantation 2006; 82:S6-S8.
24. Saethre M, Lea T, Borgen MS, et al. Human complement-activating immunoglobulin (Ig)G3 antibodies are essential for porcine endothelial cell activation. Xenotransplantation 2006; 13:215-223. (Pubitemid 43824211)
25. Schneider MK, Seebach JD. Current cellular innate immune hurdles in pig-toprimate xenotransplantation. Curr Opin Organ Transplant 2008; 13:171-177.
26. Le Bas-Bernardet S, Blancho G. Current cellular immunological hurdles in pig-to-primate xenotransplantation. Transpl Immunol 2008. [Epub ahead of print]
27. Kuwaki K, Tseng YL, Dor FJ, et al. Heart transplantation in baboons using alpha1,3-galactosyltransferase gene-knockout pigs as donors: initial experience. Nat Med 2005; 11:29-31. (Pubitemid 40215833)
28. Tseng YL, Kuwaki K, Dor FJ, et al. alpha1,3-Galactosyltransferase geneknockout pig heart transplantation in baboons with survival approaching 6 months. Transplantation 2005; 80:1493-1500. (Pubitemid 41803633)
29. Hara H, Long C, Lin YJ, Tai HC, Ezzelarab M, Ayares D, Cooper DK. In vitro investigation of pig cells for resistance to human antibody-mediated rejection. Transpl Int 2008; 21:1163-1174. This in-vitro study shows that transgenic CD46 expression on the GalT KO background significantly protects pig endothelial cells from lysis by human serum. It strongly supports the argument that expression of human complement regulatory factors will be a critical adjunct to the deletion of GalT.
30. Rosengard AM, Cary N, Horsley J, et al. Endothelial expression of human decay accelerating factor in transgenic pig tissue: a potential approach for human complement inactivation in discordant xenografts. Transplant Proc 1995; 27:326-327.
31. Morgan BP, Berg CW, Harris CL. 'Homologous restriction' in complement lysis: roles of membrane complement regulators. Xenotransplantation 2005; 12:258-265.
32. Siegel JB, Grey ST, Lesnikoski BA, et al. Xenogeneic endothelial cells activate human prothrombin. Transplantation 1997; 64:888-896. (Pubitemid 27422273)
33. Roussel JC, Moran CJ, Salvaris EJ, et al. Pig thrombomodulin binds human thrombin but is a poor cofactor for activation of human protein C and TAFI. Am J Transplant 2008; 8:1101-1112. This study dissects the molecular incompatibility between pig thrombomodulin and human thrombin and demonstrates for the first time that the pig regulator is an inefficient cofactor for activating human TAFI in addition to protein C.
34. Huang Y, Yin H, Han J, et al. Extracellular hmgb1 functions as an innate immune-mediator implicated in murine cardiac allograft acute rejection. Am J Transplant 2007; 7:799-808. (Pubitemid 46481209)
35. Moser B, Szabolcs MJ, Ankersmit HJ, et al. Blockade of RAGE suppresses alloimmune reactions in vitro and delays allograft rejection in murine heart transplantation. Am J Transplant 2007; 7:293-302. (Pubitemid 46096322)
36. Kawahara K, Setoyama K, Kikuchi K, et al. HMGB1 release in co-cultures of porcine endothelial and human T cells. Xenotransplantation 2007; 14:636-641. HMGB1 is a potent pro-inflammatory molecule that has been implicated in transplant rejection, so the release of pig and human HMGB1 detected in this co-culture system may be relevant to xenograft rejection. (Pubitemid 350076138)
37. Kopp CW, Siegel JB, Hancock WW, et al. Effect of porcine endothelial tissue factor pathway inhibitor on human coagulation factors. Transplantation 1997; 63:749-758. (Pubitemid 27132211)
38. Lee KF, Salvaris EJ, Roussel JC, et al. Recombinant pig TFPI efficiently regulates human tissue factor pathways. Xenotransplantation 2008; 15:191-197. This paper refutes the long-held view that pig TFPI is incompatible with human tissue factor. It does not, however, negate the case for transgenic expression of TFPI on pig endothelium.
39. Lin CC, Chen D, McVey JH, et al. Expression of tissue factor and initiation of clotting by human platelets and monocytes after incubation with porcine endothelial cells. Transplantation 2008; 86:702-709. This study shows that resting pig endothelial cells promote the expression of TF on human platelets and monocytes even in the absence of human serum, raising concerns that thrombosis may remain a problem for xenografts even in the absence of a humoral response.
40. Yang YG, Sykes M. Xenotransplantation: current status and a perspective on the future. Nat Rev Immunol 2007; 7:519-531. (Pubitemid 46987781)
41. Lilienfeld BG, Crew MD, Forte P, et al. Transgenic expression of HLA-E single chain trimer protects porcine endothelial cells against human natural killer cellmediated cytotoxicity. Xenotransplantation 2007; 14:126-134. (Pubitemid 46457451)
42. Wang H, VerHalen J, Madariaga ML, et al. Attenuation of phagocytosis of xenogeneic cells by manipulating CD47. Blood 2007; 109:836-842. (Pubitemid 46105989)
43. Sis B, Famulski KS, Allanach KL, et al. IFN-gamma prevents early perforingranzyme- mediated destruction of kidney allografts by inducing donor class I products in the kidney. Am J Transplant 2007; 7:2301-2310. (Pubitemid 47347869)
44. Famulski KS, Sis B, Billesberger L, Halloran PF. Interferon-gamma and donor MHC class I control alternative macrophage activation and activin expression in rejecting kidney allografts: a shift in the Th1-Th2 paradigm. Am J Transplant 2008; 8:547-556. This study, following on from previous work by the same group, shows that defective IFNg signalling - as might be expected in pig-to-human xenografts - results in alternative macrophage activation and early microcirculatory collapse in murine renal allografts. (Pubitemid 351287549)
45. Ramackers W, Friedrich L, Tiede A, et al. Effects of pharmacological intervention on coagulopathy and organ function in xenoperfused kidneys. Xenotransplantation 2008; 15:46-55. (Pubitemid 351360241)
46. Kim YT, Lee HJ, Lee SW, et al. Pretreatment of porcine pulmonary xenograft with desmopressin: a novel strategy to attenuate platelet activation and systemic intravascular coagulation in an ex-vivo model of swine-to-human pulmonary xenotransplantation. Xenotransplantation 2008; 15:27-35.
47. Brandl U, Jockle H, Erhardt M, et al. Reduced fibrin deposition and intravascular thrombosis in hDAF transgenic pig hearts perfused with tirofiban. Transplantation 2007; 84:1667-1676.
48. Byrne GW, Davies WR, Oi K, et al. Increased immunosuppression, not anticoagulation, extends cardiac xenograft survival. Transplantation 2006; 82:1787-1791. (Pubitemid 46035668)
49. Cozzi E, Simioni P, Boldrin M, et al. Effects of long-term administration of high-dose recombinant human antithrombin in immunosuppressed primate recipients of porcine xenografts. Transplantation 2005; 80:1501-1510. (Pubitemid 41803634)
50. Brunetti D, Perota A, Lagutina I, et al. Transgene expression of green fluorescent protein and germ line transmission in cloned pigs derived from in vitro transfected adult fibroblasts. Cloning Stem Cells 2008; 10:409-419. This paper describes a robust method for cloning pigs from transfected adult fibroblasts, representing an important technological advance in the genetic manipulation of pigs.
51. Matsunami K, Miyagawa S, Nakagawa K, et al. Molecular cloning of pigGnT-I and I.2: an application to xenotransplantation. Biochem Biophys Res Commun 2006; 343:677-683.
52. Brown SJ, Miller AM, Cowan PJ, et al. Altered immune system glycosylation causes colitis in alpha1,2-fucosyltransferase transgenic mice. Inflamm Bowel Dis 2004; 10:546-556.
53. Moore GT, Brown SJ, Winterhalter AC, et al. Glycosylation changes in hFUT1 transgenic mice increase TCR signalling and apoptosis resulting in thymocyte maturation arrest. Mol Immunol 2008; 45:2401-2410.
54. Loveland BE, Milland J, Kyriakou P, et al. Characterization of a CD46 transgenic pig and protection of transgenic kidneys against hyperacute rejection in nonimmunosuppressed baboons. Xenotransplantation 2004; 11:171-183. (Pubitemid 38282268)
55. Cowan PJ, Aminian A, Barlow H, et al. Renal xenografts from tripletransgenic pigs are not hyperacutely rejected but cause coagulopathy in nonimmunosuppressed baboons. Transplantation 2000; 69:2504-2515. (Pubitemid 30482015)
56. Markiewski MM, Nilsson B, Ekdahl KN, et al. Complement and coagulation: strangers or partners in crime? Trends Immunol 2007; 28:184-192.
57. Cowan PJ, d'Apice AJ. The coagulation barrier in xenotransplantation: incompatibilities and strategies to overcome them. Curr Opin Organ Transplant 2008; 13:178-183.
58. Dwyer KM, Robson SC, Nandurkar HH, et al. Thromboregulatory manifestations in human CD39 transgenic mice and the implications for thrombotic disease and transplantation. J Clin Invest 2004; 113:1440-1446.
59. d'Apice AJF, Cowan PJ. Xenotransplantation: the next generation of engineered animals. Transpl Immunol 2008. [Epub ahead of print]
60. Chen D, Weber M, McVey JH, et al. Complete inhibition of acute humoral rejection using regulated expression of membrane-tethered anticoagulants on xenograft endothelium. Am J Transplant 2004; 4:1958-1963. (Pubitemid 39611622)